Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06027788 · ClinicalTrials.gov registry record · NA

CTSN Embolic Protection Trial

A NA study of Coronary Artery Disease and Acute Kidney Injury, sponsored by Icahn School of Medicine at Mount Sinai.

Recruiting
Registry status
NA
Development phase
842
Enrollment target
20
Study locations

NCT06027788 is a NA study of Coronary Artery Disease and Acute Kidney Injury that is actively recruiting participants, run by Icahn School of Medicine at Mount Sinai. The registered enrollment target is 842 participants, below the 1,283-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (34% lower). The trial reports 20 study locations across 14 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06027788, a NA study of Coronary Artery Disease and Acute Kidney Injury, is actively recruiting participants, sponsored by Icahn School of Medicine at Mount Sinai.

RECRUITING
Registry status
NA
Development phase
842 participants
Enrollment target
20
Study locations

Study Summary

This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.

Conditions Studied

Coronary Artery Disease Acute Kidney Injury Ischemic Stroke Delirium Heart Valve Disease

Interventions

  • DEVICE CardioGard Embolic Protection Cannula
  • DEVICE Standard Aortic Cannula

Study Locations (20)

New York

  • Columbia University Medical Center - New York
  • New York Presbyterian-Cornell Medical Center - New York
  • NYU Langone Hospital Brooklyn - New York
  • Northwell Health - New York
  • Montefiore Medical Center - The Bronx

Indiana

  • Indiana University - Bloomington
  • Indiana Ohio Heart - Fort Wayne

Maryland

  • Johns Hopkins Medicine - Baltimore
  • University of Maryland - College Park

Arkansas

  • CHI St. Vincent Heart Institute - North Little Rock

California

  • Keck Hospital of the University of Southern California - Los Angeles

Georgia

  • Emory University - Atlanta

Louisiana

  • Ochsner Clinic - New Orleans

Maine

  • Maine Medical Center - Portland

Trial Details

FieldValue
Enrollment Target 842 participants
Start Date 2023-09-18
Est. Completion 2027-04-01
Phase NA

Sponsor

Icahn School of Medicine at Mount Sinai

708 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06027788

The ClinicalTrials.gov registry entry for NCT06027788 describes a study currently listed as recruiting, categorized as NA. The registered enrollment target is 842 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,283-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (34% lower). The listed sponsor is Icahn School of Medicine at Mount Sinai, which has 708 total studies on file at ClinicalTrials.gov.

The record links to 5 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 2 interventions - of which CardioGard Embolic Protection Cannula is the first listed.

NCT06027788 reports 20 study locations spanning 14 distinct geographic areas - top geographies include New York, Indiana, Maryland.

Frequently Asked Questions

What is clinical trial NCT06027788 about?

NCT06027788 is a clinical study titled "CTSN Embolic Protection Trial". This is a prospective, multi-center, randomized effectiveness trial of the CardioGard Embolic Protection Cannula in high-risk valve surgery patients.

What is the current status of trial NCT06027788?

This trial is currently recruiting. It is a NA study. The enrollment target is 842 participants. The study started on 2023-09-18. Estimated completion is 2027-04-01.

What conditions does trial NCT06027788 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Acute Kidney Injury, Ischemic Stroke, Delirium, Heart Valve Disease.

What interventions are being tested in trial NCT06027788?

The interventions under investigation include: CardioGard Embolic Protection Cannula (DEVICE), Standard Aortic Cannula (DEVICE).

Who is sponsoring clinical trial NCT06027788?

This trial is sponsored by Icahn School of Medicine at Mount Sinai, which has 708 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06027788 being conducted?

This trial has 20 study locations across Arkansas, California, Georgia, Indiana, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Coronary Artery Disease

All registered trials for this condition

Acute Kidney Injury

All registered trials for this condition

Arkansas

All trials with a study site in Arkansas

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.